Replimune Group (NASDAQ: REPL) net income
Replimune Group reported a net loss of $313.9m for fiscal 2026; in fiscal 2025 it reported a net loss of $247.3m. Earnings per share were −$3.38.
Replimune Group's best year of the last 9 was fiscal 2018. It reported a loss in 9 of those 9 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2026 | −$313.9m | — | — | −$3.38 |
| 2025 | −$247.3m | — | — | −$3.07 |
| 2024 | −$215.8m | — | — | −$3.24 |
| 2023 | −$174.3m | — | — | −$2.99 |
| 2022 | −$118.0m | — | — | −$2.26 |
| 2021 | −$80.9m | — | — | −$1.75 |
| 2020 | −$52.6m | — | — | — |
| 2019 | −$30.8m | — | — | — |
| 2018 | −$19.7m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Replimune Group net income compared with its sector
By net income for its latest fiscal year, Replimune Group ranks 452nd of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 450th | Kymera Therapeutics | −$311.4m | −794.0% |
| 451st | Ginkgo Bioworks | −$312.8m | −183.8% |
| 452nd | Replimune Group | −$313.9m | — |
| 453rd | Cogent Biosciences | −$328.9m | — |
| 454th | Viridian Therapeutics | −$342.6m | −483.6% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Replimune Group
- How much did Replimune Group earn in fiscal 2026?
- Replimune Group reported a net loss of $313.9m for fiscal 2026. In fiscal 2025 it reported a net loss of $247.3m.
- What are the earnings per share of Replimune Group?
- They were −$3.38 in fiscal 2026, compared with −$3.07 in fiscal 2025.
- Where does Replimune Group rank in its sector by net income?
- It ranks 452nd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Replimune Group come from?
- From the annual report (Form 10-K) that Replimune Group files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Replimune Group files with the SEC. The filing for each fiscal year: 2026 · 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018. More on Replimune Group: the Replimune Group page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.